Kulvinder Kochar Kaur1*, Gautam Allahbadia2 and Mandeep Singh3
1Scientific Director, Dr Kulvinder Kaur Centre for Human Reproduction, Jalandhar, Punjab, India
2Scientific Director, Rotunda-A Centre for Human Reproduction, Mumbai, India
33Consultant Neurologist, Swami Satyanand Hospital, Jalandhar, Punjab, India
*Corresponding Author: Kulvinder Kochar Kaur, Scientific Director, Dr Kulvinder Kaur Centre for Human Reproduction, Jalandhar, Punjab, India.
Received: October 14, 2019; Published: December 05, 2019
The metabolic syndrome (MetS) by definition is the presence of 3/5 symptoms at the same time, like abnormal fasting glycaemia, abdominal obesity, increasedblood pressure (BP), hypertrigyceridaemia and low amounts of high density lipoprotein ( HDL) . With MetS chances of acquiring serious problems like type2 diabetes mellitus (T2DM), coronary heart disease (CHD), Ischemic stroke and atherosclerosis is present. Statistics conducted recently display that MetS takes place in 20-25% of adult population which has taken epidemic levels . With it becoming a big therapeutic problem in developed countries, emphasis is being laid on producing efficacious, safe cures.
Citation: Kulvinder Kochar Kaur., et al. “Utilization of a Pyrrolidin-2-One Based Nonselective α-Adrenoceptor Antagonist for Metabolic Syndrome (MetS) Therapy Along with Histamine H3 Inverse Agonist Pitolistant in High Fat Diet Induced Obesity in Mice and Future Role in Humanbeing".Acta Scientific Nutritional Health 4.1 (2020): 30-33.
Copyright: © 2020 Kulvinder Kochar Kaur., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.